BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 22206795)

  • 21. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
    Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
    Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
    Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
    Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
    Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass balance, metabolic disposition, and pharmacokinetics of [
    Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects.
    Disanto AR; Golden G
    Clin Drug Investig; 2009; 29(8):539-49. PubMed ID: 19591515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
    Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
    Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of LBPT and its primary metabolites, as well as tolerability in the first-in-human study.
    Wang H; Liu H; Liu M; Wang W; Zhu L; Huang H; Hu P; Jiang J
    Eur J Pharm Sci; 2017 Mar; 100():87-93. PubMed ID: 28057550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
    Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
    Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions.
    Martínez-Sellés M; Datino T; Figueiras-Graillet L; Gama JG; Jones C; Franklin R; Fernández-Avilés F
    Clin Drug Investig; 2013 Jan; 33(1):45-54. PubMed ID: 23184666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
    Johansson S; Read J; Oliver S; Steinberg M; Li Y; Lisbon E; Mathews D; Leese PT; Martin P
    Clin Pharmacokinet; 2014 Sep; 53(9):837-47. PubMed ID: 25117183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vandetanib: in medullary thyroid cancer.
    Frampton JE
    Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
    Zhu Y; Statkevich P; Cutler DL
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):539-47. PubMed ID: 17966839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.